Mayo Clinic News Network

News Resources


Share this:

Posted by Kelley Luckstein (@KelleyLuckstein) · Tue, Jan 7 at 1:30pm EDT

Combined Therapy Benefits Cigarette Smokers Trying to Quit Compared to Monotherapy

ROCHESTER, Minn. — Jan. 7, 2014 — Among cigarette smokers, combining the smoking cessation medications varenicline and bupropion, compared with varenicline alone, resulted in higher smoking abstinence rates for one outcome but not the other at three and six months; rates were similar at one year, according to a Mayo Clinic study published this month in JAMA.

“We were interested in seeing if combining different medications together can improve the ability of patients to quit over and above single drug therapy,” says lead author Jon Ebbert, M.D., Mayo Clinic Nicotine Dependence Center. “What we found was an increase in quit rates, and the increase in quit rates was particularly strong in heavier and more dependent smokers.”fist smashing cigarettes

The study authors looked at the efficacy of combining the medications varenicline and bupropion SR (sustained-release) for smoking cessation, compared with varenicline alone (monotherapy). In addition, the research team analyzed data based on participants’ smoking rate and level of nicotine dependence.

Cigarette smokers were randomized to 12 weeks of varenicline and bupropion SR or varenicline and placebo with follow-up through 52 weeks. The primary outcome was smoking abstinence rates at week 12, defined as prolonged abstinence (no smoking from two weeks after the target quit date) and seven-day point-prevalence abstinence (no smoking past seven days). Outcomes were confirmed with an exhaled breath test for carbon monoxide.

Combination therapy was associated with significantly higher prolonged smoking abstinence rates at 12 (53 percent vs. 43.2 percent) and 26 weeks (36.6 percent vs. 27.6 percent) compared with varenicline alone. No significant differences were observed between the two groups at any time point for seven-day point-prevalence smoking abstinence. Anxiety was reported more commonly with combination therapy than with varenicline monotherapy (7.2 percent vs. 3.1 percent), as were depressive symptoms (3.6 percent vs. 0.8 percent).

Additional analyses revealed that the beneficial effects of combination therapy were stronger in heavier and more dependent smokers.

“For lighter smokers, using varenicline alone is just as effective as using both medications together,” says Dr. Ebbert. “But, if you’re a heavy smoker, you really should consider using combination therapy to increase your success of quitting.”

The study was supported by National Institutes of Health grant CA138417. Medication (varenicline) was supplied by Pfizer.

Other authors include Dorothy Hatsukami, Ph.D., University of Minnesota; Sharon Allen, M.D., Ph.D., Family Medicine and Community Health, University of Minnesota; Ivana Croghan, Ph.D.; Darrell Schroeder; J. Taylor Hays, M.D.; and Richard Hurt, M.D., all from Mayo Clinic.

###

About Mayo Clinic
Recognizing 150 years of serving humanity in 2014, Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit 150years.mayoclinic.org, MayoClinic.org or http://newsnetwork.mayoclinic.org/.

MEDIA CONTACT:
Kelley Luckstein, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu

bupropion cigarette smoking Dr. Jon Ebbert JAMA Mayo Clinic Nicotine Dependence Center nicotine dependence quitting smoking smoking abstinence smoking cessation smoking cessation medications varenicline Minnesota news release News Release Mayo Clinic Cancer Center

 

Have something to say? Please login or register to respond.